Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Ying Du Sells 5,576 Shares of Zai Lab (NASDAQ:ZLAB) Stock
06:26am, Sunday, 05'th Apr 2026
Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) CEO Ying Du sold 5,576 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $20.
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab's inve
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages
04:43am, Wednesday, 01'st Apr 2026
Shares of Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the stock,
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-developed investigational oncology therapies will be presente
Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript
01:47pm, Thursday, 26'th Feb 2026
Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
11:01am, Thursday, 26'th Feb 2026
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with W
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
07:00am, Thursday, 26'th Feb 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highligh
Baron Emerging Markets Fund Q4 2025 Portfolio Activity
01:56pm, Sunday, 22'nd Feb 2026
During Q4, Baron Emerging Markets Fund added a few new investments to existing themes while also increasing exposure to several positions that we established in earlier periods. SK hynix has emerged a
Zai Lab Limited (ZLAB) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
04:44pm, Friday, 20'th Feb 2026
Zai Lab Limited (ZLAB) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $51.59 Consensus Price Target from Analysts
02:24am, Friday, 13'th Feb 2026
Shares of Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are presently covering the company, Mark
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
08:30am, Tuesday, 10'th Feb 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2025 financial results and provide recent
$207B Market Shift: The Race for Fast Track Approval in Oncology
09:35am, Thursday, 05'th Feb 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency
Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8%
02:20am, Monday, 19'th Jan 2026
Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totaling 4,248
Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:15pm, Tuesday, 13'th Jan 2026
Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 13'th Jan 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today provided an update on the Company's 2026 strategic priorities and clinical development progress. These up
